Clinical Trial Detail

NCT ID NCT02650999
Title Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas
Recruitment Active, not recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

mantle cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.